门静脉血栓病因及危险因素研究进展*

doi:10.3969/j.issn.1672-5069.2019.06.001

Abstract

Chen Shuai, Yang Changqing.. Pathogenesis and risk factors of portal vein thrombosis[J]. Journal of Practical Hepatology, 2019, 22(6): 761-764.

[1] Balford GW,Stewart TG. Case of enlarged spleen complicated with ascites,both depending upon varicose dilatation and thrombosis of the portal vein. Edinb Med J,1869,14(7):589-598.
[2] Okuda K,Ohnishi K,Kimura K,et al.Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. Gastroenterology,1985,89(2):279-286.
[3] Ogren M,Bergqvist D,Bjorck M,et al.Portal vein thrombosis:Prevalence,patient characteristics and lifetime risk:A population study based on 23796 consecutive autopsies. World J Gastroenterol,2006,12(13):2115-2119.
[4] Amitrano L,Guardascione MA,Brancaccio V,et al.Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol,2004,40(5):736-741.
[5] Harding DJ,Perera MT,Chen F,et al.Portal vein thrombosis in cirrhosis:Controversies and latest developments. World J Gastroenterol,2015,21(22):6769-6784.
[6] Violi F,Corazza GR,Caldwell SH,et al.Portal vein thrombosis relevance on liver cirrhosis:Italian Venous Thrombotic Events Registry. Intern Emerg Med,2016,11(8):1059-1066.
[7] Ponziani FR,Zocco MA,Campanale C,et al.Portal vein thrombosis:Insight into physiopathology,diagnosis,and treatment. World J Gastroenterol,2010,16(2):143-155.
[8] 姚戈冰,鲁建国.门静脉血栓的发病机制及诊治.肝胆外科杂志,2009,17(2):151-154.
[9] García-Pagán JC,Busacarini E,Janssen HLA,et al.EASL Clinical Practice Guidelines:Vascular diseases of the liver. J Hepatol,2016,64(1):179-202.
[10] DeLeve LD,Valla DC,Garcia-Tsao G,et al. Vascular disorders of the liver. Hepatology,2009,49(5):1729-1764.
[11] Basit SA,Stone CD,Gish R.Portal vein thrombosis. Clin Liver Dis,2015,19(1):199-221.
[12] Trebicka J,Strassburg CP.Etiology and complications of portal vein thrombosis.Viszeralmedizin,2014,30(6):375-380.
[13] Battistelli S,Coratti F,Gori T.Porto-spleno-mesenteric venous thrombosis. Int Angiol,2011,30(1):1-11.
[14] 熊静平,张跃新.肝硬化合并门静脉血栓的研究现状.临床肝胆病杂志,2016,32(6):1075-1078.
[15] Riva N,Donadini MP,Dentali F,et al.Clinical approach to splanchnic vein thrombosis:Risk factors and treatment. Thromb Res,2012,130(Suppl 1):S1-S3.
[16] Zocco MA,Di Stasio E,De Cristofaro R,et al.Thrombotic risk factors in patients with liver cirrhosis:Correlation with MELD scoring system and portal vein thrombosis development. J Hepatol,2009,51(4):682-689.
[17] 刘明涛,韩国宏,王建宏,等.肝硬化门静脉高压患者门静脉压力与血流动力学的关系.中华肝脏病杂志,2004,12(8):504-505.
[18] Maruyama H,Okugawa H,Takahashi M,et al.De novo portal vein thrombosis in virus-related cirrhosis:Predictive factors and long-term Outcomes. Am J Gastroenterol,2013,108(4):568-574.
[19] Zampino R,Lebano R,Coppola N,et al.The use of nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients. Saudi J Gastroenterol,2018,24(1):25-29.
[20] Qi X,Chen H,Han G.Effect of antithrombin,protein C and protein S on portal vein thrombosis in liver cirrhosis:a meta-a
nalysis. Am J Med Sci,2013,346(1):38-44.
[21] 卢晓敏,王振宁,杨军. 肝硬化患者血栓前状态分子标志物对门静脉血栓形成的监测意义. 临床肝胆病杂志,2015,31(3):404-406.
[22] 李兰娟. 中国消化道微生态调节剂临床应用共识(2016年版).中国微生态学杂志,2016,28( 6):621-631.
[23] Violi F,Lip GY,Cangemi R.Endotoxemia as a trigger of thrombosis in cirrhosis. Haematologica,2016,101(4):e162-e163.
[24] 王新保,杨镇,李德旭,等. 门静脉高压症病人肝内血管内皮细胞凋亡的研究. 中华肝胆外科杂志,2002,8(1):28-30.
[25] Northup PG,Caldwell SH.Coagulation in liver disease:a guide for the clinician. Clin Gastroenterol Hepatol,2013,11(9):1064-1074.
[26] Caldwell SH,Hoffman M,Lisman T,et al.Coagulation disorders and hemostasis in liver disease:Pathophysiology and critical assessment of current management. Hepatology,2006,44(4):1039-1046.
[27] Chen H,Liu L,Qi X,et al.Imbalance of pro-vs. anti-coagulation factors in Chinese patients with Budd-Chiari syndrome and non-cirrhotic portal vein thrombosis. PLoS One,2015,10(3):e0119909.
[28] 田颖,陈文明,张冬磊,等. 肝硬化患者门静脉血栓形成的多因素分析. 中国医师进修杂志,2012,35(22):21-24.
[29] Abdel-Razik A,Mousa N,Elhelaly R,et al.De-novo portal vein thrombosis in liver cirrhosis:risk factors and correlation with the Model for End-stage Liver Disease scoring system.Eur J Gastroenterol Hepatol,2015,27(5):585-592.
[30] Qi X,Han G,Ye C,et al.Splenectomy causes 10-fold increased risk of portal venous system thrombosis in liver cirrhosis patients. Med Sci Monit,2016,22:2528-2550.
[31] 孙隆慈,罗蒙. 门静脉高压症中门静脉血栓的发生机制及诊治进展. 肝胆胰外科杂志,2011,23(1):84-86.
[32] 匡洁,杨卫平,陈皓,等. 门静脉高压症术后门静脉血栓形成的危险因素分析. 外科理论与实践,2012,17(6):634-638.
[33] Kuroki T,Kitasato A,Tokunaga T,e t al. Predictors of portal and splenic vein thrombosis after laparoscopic splenectomy:a retrospective analysis of a single-center experience. Surg Today,2018,48(8):804-809.
[34] Danno K,Ikeda M,Sekimoto M,et al.Diameter of splenic vein is a risk factor for portal or splenic vein thrombosis after laparoscopic splenectomy.Surgery,2009,145(5):457-464.
[35] 陈炜,吴志勇.肝硬化门静脉高压症术后门静脉血栓形成的机制. 肝胆外科杂志,2015,23(5):321-323.
[36] Wang L,Liu GJ,Chen YX,et al.Combined use of D-dimer and P-selectin for the diagnosis of splenic or portal vein thrombosis following splenectomy. Thromb Res,2010,125(5):e206-e209.
[37] Wei Y,Chen X,Shen H,et al.P-Selectin Level at First and Third Day After Portal Hypertensive Splenectomy for Early Prediction of Portal Vein Thrombosis in Patients With Cirrhosis. Clin Appl Thromb Hemost,2018:1-8.
[38] Sobhonslidsuk A,Reddy KR.Portal vein thrombosis:a concise review. Am J Gastroenterol,2002,97(3):535-541.
[39] Zanetto A,Campello E,Spiezia L,et al.Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma.Cancers,2018,10(11):450.
[40] Falanga A.Mechanisms of Hypercoagulation in Malignancy and during Chemotherapy. Haemostasis,1998,28(Suppl 3):50-60.
[41] Plessier A,Rautou PE,Valla DC.Management of hepatic vascular diseases. J Hepatol,2012,56(Suppl 1):S25-S38.
[42] Kumar A,Sharma P,Arora A.Review article:portal vein obstruction-epidemiology,pathogenesis,natural history,prognosis and treatment. Aliment Pharmacol Ther,2015,41(3):276-292.
[43] Qi X,Ren W,De Stefano V,et al.Associations of Coagulation Factor V Leiden and Prothrombin G20210A Mutations With Budd-Chiari Syndrome and Portal Vein Thrombosis:A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol,2014,12(11):1801-1812,e1807.
[44] Qi X,De Stefano V,Wang J,et al.Prevalence of inherited antithrombin,protein C,and protein S deficiencies in portal vein system thrombosis and Budd-Chiari syndrome:A systematic review and meta-analysis of observational studies. J Gastroenterol Hepatol,2013,28(3):432-442.

Pathogenesis and risk factors of portal vein thrombosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[3]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[4]	Xu Qilin, Hao Shaohuan, Ran Bo. Risk factors of portal vein thrombosis after splenectomy in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2019, 22(5): 708-711.
[5]	Qiu Jun, Wang Xueqing, Zhang Bo, et al. Percutaneous choledocholithotomy for the treatment of patients with intrahepatic bile duct stones [J]. Journal of Practical Hepatology, 2019, 22(5): 744-747.
[6]	Huang Zhiyin, Li Jing. Splenectomy in patients with liver cirrhosis：the pros and cons [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 459-461.
[7]	Zhang Wei, Shi Junmei, Wang Qian. Fisk factors for occurrence of hyperbilirubinemia in neonates [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 534-536.
[8]	Li Fang, Zou Guizhou, Ye Jun, et al. Clinical features and risk factors of patients with decompensated cirrhosis and sepsis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 557-560.
[9]	Liu Yanjun, Li Guangming. Prophylaxis and management of patients with portal vein thrombosis complicting liver cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 605-608.
[10]	Du Min, Zhou Min, Ji Zongshu. Clinical features and risk factors of liver injuries in patients with sepsis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 369-372.
[11]	Xiao Ke, Pan Zhihua, Tu Bo. Predictive value of preoperative CT/MRI indicators for portal vein thrombosis in patients with liver cirrhosis after splenectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 417-420.
[12]	Liu Wenbo, Zhang Jianye, Bao Jiwu. Analysis of risk factors for stone recurrence in patients with common bile duct stones after ERCP and EST therapy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 437-440.
[13]	Wu Yaping, Zhou Bingqing, Jiang Peili. Risk factors of severe hepatic fibrosis in patients with chronic hepatitis C with previous paid blood donation [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 196-199.
[14]	Zhao Xiaofei, Lin Dongdong, Li Ning, Zang Yunjin, Guo Qingliang, Wu Juanshan. Application of warfarin in dealing with portal vein thrombosis in patients with liver cirrhosis after splenectomy and devascularization [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 240-243.
[15]	Wang Junyan, Chen Jianting, Zhang Ting, et al.. Risk factors of nosocomial infections in patients with hepatitis B liver cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 101-104.